BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201

Reuters
10 Feb
BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201

Feb 10 (Reuters) - Immix Biopharma Inc IMMX.O:

  • IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR NXC-201, STERICALLY-OPTIMIZED CAR-T FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

  • IMMIX BIOPHARMA INC: ENROLLMENT IN NEXICART-2 STUDY ACCELERATING; NEXT UPDATE PLANNED FOR H1 2025

Source text: ID:nGNXbjs757

Further company coverage: IMMX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10